{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T14:39:52Z","timestamp":1787668792978,"version":"build-2736575974"},"reference-count":34,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007316","name":"National Cancer Institute Division of Cancer Prevention","doi-asserted-by":"publisher","award":["UG1CA189867"],"award-info":[{"award-number":["UG1CA189867"]}],"id":[{"id":"10.13039\/100007316","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["U10CA180822"],"award-info":[{"award-number":["U10CA180822"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["U24CA196067"],"award-info":[{"award-number":["U24CA196067"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["P30CA240139"],"award-info":[{"award-number":["P30CA240139"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01 CA240582-01"],"award-info":[{"award-number":["R01 CA240582-01"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["U10CA180868"],"award-info":[{"award-number":["U10CA180868"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","euoncology.europeanurology.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Urology Oncology"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1016\/j.euo.2024.10.017","type":"journal-article","created":{"date-parts":[[2024,11,13]],"date-time":"2024-11-13T15:48:42Z","timestamp":1731512922000},"page":"413-421","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Biopsy-based Basal-luminal Subtyping Classifier in High-risk Prostate Cancer: A Combined Analysis of the NRG Oncology\/RTOG 9202, 9413, and 9902 Phase 3 Trials"],"prefix":"10.1016","volume":"9","author":[{"given":"Krishnan R.","family":"Patel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul L.","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James A.","family":"Proudfoot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan Dal","family":"Pra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel E.","family":"Spratt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan","family":"Pollack","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Howard M.","family":"Sandler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason A.","family":"Efstathiou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Colleen","family":"Lawton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffry P.","family":"Simko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seth A.","family":"Rosenthal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenneth L.","family":"Zeitzer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucas C.","family":"Mendez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan C.","family":"Hartford","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William A.","family":"Hall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anand B.","family":"Desai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie L.","family":"Pugh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elai","family":"Davicioni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Phuoc T.","family":"Tran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felix Y.","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.euo.2024.10.017_b0005","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.eururo.2023.04.024","article-title":"Androgen deprivation and radiotherapy with or without docetaxel for localized high-risk prostate cancer: long-term follow-up from the randomized NRG Oncology RTOG 0521 trial","volume":"84","author":"Sartor","year":"2023","journal-title":"Eur Urol"},{"key":"10.1016\/j.euo.2024.10.017_b0010","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1056\/NEJMoa2214122","article-title":"Fifteen-year outcomes after monitoring, surgery, or radiotherapy for prostate cancer","volume":"388","author":"Hamdy","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.euo.2024.10.017_b0015","volume":"1024","author":"Amin","year":"2017"},{"key":"10.1016\/j.euo.2024.10.017_b0020","doi-asserted-by":"crossref","first-page":"4567","DOI":"10.1200\/JCO.2002.03.061","article-title":"Determinants of prostate cancer-specific survival after radiation therapy for patients with clinically localized prostate cancer","volume":"20","author":"D'Amico","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.euo.2024.10.017_b0025","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1016\/j.eururo.2013.03.033","article-title":"A new risk classification system for therapeutic decision making with intermediate-risk prostate cancer patients undergoing dose-escalated external-beam radiation therapy","volume":"64","author":"Zumsteg","year":"2013","journal-title":"Eur Urol"},{"key":"10.1016\/j.euo.2024.10.017_b0030","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1200\/JCO.2017.74.2940","article-title":"Development and validation of a novel integrated clinical-genomic risk group classification for localized prostate cancer","volume":"36","author":"Spratt","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.euo.2024.10.017_b0035","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1016\/S1470-2045(10)70223-0","article-title":"External irradiation with or without long-term androgen suppression for prostate cancer with high metastatic risk: 10-year results of an EORTC randomised study","volume":"11","author":"Bolla","year":"2010","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.euo.2024.10.017_b0040","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1016\/j.ijrobp.2017.02.004","article-title":"Duration of androgen deprivation in locally advanced prostate cancer: long-term update of NRG Oncology RTOG 9202","volume":"98","author":"Lawton","year":"2017","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.euo.2024.10.017_b0045","doi-asserted-by":"crossref","first-page":"2516","DOI":"10.1056\/NEJMoa0810095","article-title":"Duration of androgen suppression in the treatment of prostate cancer","volume":"360","author":"Bolla","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.euo.2024.10.017_b0050","doi-asserted-by":"crossref","DOI":"10.1016\/j.radonc.2023.109544","article-title":"ESTRO-ACROP recommendations for evidence-based use of androgen deprivation therapy in combination with external-beam radiotherapy in prostate cancer","volume":"183","author":"Schmidt-Hegemann","year":"2023","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.euo.2024.10.017_b0055","unstructured":"National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: prostate cancer (version 2.2023). https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/prostate.pdf."},{"key":"10.1016\/j.euo.2024.10.017_b0060","doi-asserted-by":"crossref","first-page":"2169","DOI":"10.1002\/cncr.34790","article-title":"A novel prostate cancer subtyping classifier based on luminal and basal phenotypes","volume":"129","author":"Weiner","year":"2023","journal-title":"Cancer"},{"key":"10.1016\/j.euo.2024.10.017_b0065","doi-asserted-by":"crossref","first-page":"3972","DOI":"10.1200\/JCO.2003.11.023","article-title":"Phase III trial of long-term adjuvant androgen deprivation after neoadjuvant hormonal cytoreduction and radiotherapy in locally advanced carcinoma of the prostate: the Radiation Therapy Oncology Group Protocol 92\u201302","volume":"21","author":"Hanks","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.euo.2024.10.017_b0070","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1200\/JCO.18.00154","article-title":"Time interval to biochemical failure as a surrogate end point in locally advanced prostate cancer: analysis of randomized trial NRG\/RTOG 9202","volume":"37","author":"Dignam","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.euo.2024.10.017_b0075","doi-asserted-by":"crossref","first-page":"1904","DOI":"10.1200\/JCO.2003.05.004","article-title":"Phase III trial comparing whole-pelvic versus prostate-only radiotherapy and neoadjuvant versus adjuvant combined androgen suppression: Radiation Therapy Oncology Group 9413","volume":"21","author":"Roach","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.euo.2024.10.017_b0080","doi-asserted-by":"crossref","first-page":"1504","DOI":"10.1016\/S1470-2045(18)30528-X","article-title":"Sequence of hormonal therapy and radiotherapy field size in unfavourable, localised prostate cancer (NRG\/RTOG 9413): long-term results of a randomised, phase 3 trial","volume":"19","author":"Roach","year":"2018","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.euo.2024.10.017_b0085","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1016\/j.ijrobp.2015.05.024","article-title":"A phase 3 trial of 2 years of androgen suppression and radiation therapy with or without adjuvant chemotherapy for high-risk prostate cancer: final results of Radiation Therapy Oncology Group phase 3 randomized trial NRG Oncology RTOG 9902","volume":"93","author":"Rosenthal","year":"2015","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.euo.2024.10.017_b0090","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1001\/jamaoncol.2020.7671","article-title":"Validation of a 22-gene genomic classifier in patients with recurrent prostate cancer: an ancillary study of the NRG\/RTOG 9601 randomized clinical trial","volume":"7","author":"Feng","year":"2021","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.euo.2024.10.017_b0095","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1038\/pcan.2016.58","article-title":"Utilization of biopsy-based genomic classifier to predict distant metastasis after definitive radiation and short-course ADT for intermediate and high-risk prostate cancer","volume":"20","author":"Nguyen","year":"2017","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"10.1016\/j.euo.2024.10.017_b0100","doi-asserted-by":"crossref","first-page":"409","DOI":"10.2353\/jmoldx.2010.090155","article-title":"Quantitative expression profiling in formalin-fixed paraffin-embedded samples by affymetrix microarrays","volume":"12","author":"Abdueva","year":"2010","journal-title":"J Mol Diagn"},{"key":"10.1016\/j.euo.2024.10.017_b0105","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/j.ijrobp.2022.12.035","article-title":"Analysis of a biopsy-based genomic classifier in high-risk prostate cancer: meta-analysis of the NRG Oncology\/Radiation Therapy Oncology Group 9202, 9413, and 9902 phase 3 randomized trials","volume":"116","author":"Nguyen","year":"2023","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.euo.2024.10.017_b0110","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1001\/jamaoncol.2017.0751","article-title":"Associations of luminal and basal subtyping of prostate cancer with prognosis and response to androgen deprivation therapy","volume":"3","author":"Zhao","year":"2017","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.euo.2024.10.017_b0115","doi-asserted-by":"crossref","first-page":"10798","DOI":"10.1038\/ncomms10798","article-title":"Stem cell and neurogenic gene-expression profiles link prostate basal cells to aggressive prostate cancer","volume":"7","author":"Zhang","year":"2016","journal-title":"Nat Commun"},{"key":"10.1016\/j.euo.2024.10.017_b0120","unstructured":"R Foundation for Statistical Computing. R: a language and environment for statistical computing. Version 3.6.2. https:\/\/www.R-project.org\/."},{"key":"10.1016\/j.euo.2024.10.017_b0125","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1038\/s41523-019-0124-8","article-title":"Robust and interpretable PAM50 reclassification exhibits survival advantage for myoepithelial and immune phenotypes","volume":"5","author":"Mathews","year":"2019","journal-title":"NPJ Breast Cancer"},{"key":"10.1016\/j.euo.2024.10.017_b0130","doi-asserted-by":"crossref","first-page":"4948","DOI":"10.1158\/0008-5472.CAN-16-0902","article-title":"Integrated classification of prostate cancer reveals a novel luminal subtype with poor outcome","volume":"76","author":"You","year":"2016","journal-title":"Cancer Res"},{"key":"10.1016\/j.euo.2024.10.017_b0135","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1016\/j.eururo.2014.07.010","article-title":"Adverse effects of androgen deprivation therapy and strategies to mitigate them","volume":"67","author":"Nguyen","year":"2015","journal-title":"Eur Urol"},{"key":"10.1016\/j.euo.2024.10.017_b0140","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1001\/jamaoncol.2020.0109","article-title":"Association of presalvage radiotherapy PSA levels after prostatectomy with outcomes of long-term antiandrogen therapy in men with prostate cancer","volume":"6","author":"Dess","year":"2020","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.euo.2024.10.017_b0145","doi-asserted-by":"crossref","first-page":"2420","DOI":"10.1200\/JCO.2006.09.3369","article-title":"Influence of androgen suppression therapy for prostate cancer on the frequency and timing of fatal myocardial infarctions","volume":"25","author":"D'Amico","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.euo.2024.10.017_b0150","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1016\/j.eururo.2018.06.018","article-title":"Duration of androgen deprivation therapy in high-risk prostate cancer: a randomized phase III trial","volume":"74","author":"Nabid","year":"2018","journal-title":"Eur Urol"},{"key":"10.1016\/j.euo.2024.10.017_b0155","doi-asserted-by":"crossref","first-page":"3217","DOI":"10.1200\/JCO.22.02389","article-title":"Dose-escalated radiation alone or in combination with short-term total androgen suppression for intermediate-risk prostate cancer: patient-reported outcomes from NRG\/Radiation Therapy Oncology Group 0815 randomized trial","volume":"41","author":"Movsas","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.euo.2024.10.017_b0160","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1200\/JCO.20.03256","article-title":"Initial management of noncastrate advanced, recurrent, or metastatic prostate cancer: ASCO guideline update","volume":"39","author":"Virgo","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.euo.2024.10.017_b0165","unstructured":"NLoM (USA). Two studies for patients with high risk prostate cancer testing less intense treatment for patients with a low gene risk score and testing a more intense treatment for patients with a high gene risk score, the PREDICT-RT trial. https:\/\/classic.clinicaltrials.gov\/ct2\/show\/NCT04513717."},{"key":"10.1016\/j.euo.2024.10.017_b0170","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1016\/j.eururo.2017.05.009","article-title":"Ability of a genomic classifier to predict metastasis and prostate cancer-specific mortality after radiation or surgery based on needle biopsy specimens","volume":"72","author":"Nguyen","year":"2017","journal-title":"Eur Urol"}],"container-title":["European Urology Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2588931124002463?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2588931124002463?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T02:36:05Z","timestamp":1778898965000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2588931124002463"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":34,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["S2588931124002463"],"URL":"https:\/\/doi.org\/10.1016\/j.euo.2024.10.017","relation":{},"ISSN":["2588-9311"],"issn-type":[{"value":"2588-9311","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Biopsy-based Basal-luminal Subtyping Classifier in High-risk Prostate Cancer: A Combined Analysis of the NRG Oncology\/RTOG 9202, 9413, and 9902 Phase 3 Trials","name":"articletitle","label":"Article Title"},{"value":"European Urology Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.euo.2024.10.017","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 European Association of Urology. Published by Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}